Gyre Therapeutics (NASDAQ:GYRE) Coverage Initiated by Analysts at Noble Financial

Noble Financial started coverage on shares of Gyre Therapeutics (NASDAQ:GYRE) in a research note published on Tuesday morning, MarketBeat.com reports. The brokerage issued an outperform rating on the stock.

Gyre Therapeutics Stock Up 9.9 %

Gyre Therapeutics stock opened at $11.35 on Tuesday. The company has a fifty day simple moving average of $11.25 and a 200-day simple moving average of $12.33. Gyre Therapeutics has a 12-month low of $8.26 and a 12-month high of $19.96.

Insider Buying and Selling

In other Gyre Therapeutics news, President Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock in a transaction on Thursday, December 26th. The shares were sold at an average price of $12.70, for a total value of $25,400.00. Following the transaction, the president now directly owns 2,928,467 shares in the company, valued at approximately $37,191,530.90. The trade was a 0.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have sold 34,054 shares of company stock worth $383,057 in the last ninety days. 19.52% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of GYRE. FMR LLC acquired a new position in Gyre Therapeutics in the third quarter valued at $47,000. Wells Fargo & Company MN increased its stake in Gyre Therapeutics by 29.4% in the fourth quarter. Wells Fargo & Company MN now owns 4,016 shares of the company’s stock valued at $49,000 after purchasing an additional 913 shares during the period. Bank of America Corp DE increased its stake in Gyre Therapeutics by 40.4% in the fourth quarter. Bank of America Corp DE now owns 6,937 shares of the company’s stock valued at $84,000 after purchasing an additional 1,996 shares during the period. Barclays PLC increased its stake in shares of Gyre Therapeutics by 281.8% during the third quarter. Barclays PLC now owns 9,288 shares of the company’s stock worth $116,000 after acquiring an additional 6,855 shares during the period. Finally, Bank of New York Mellon Corp increased its stake in shares of Gyre Therapeutics by 11.1% during the fourth quarter. Bank of New York Mellon Corp now owns 13,896 shares of the company’s stock worth $168,000 after acquiring an additional 1,389 shares during the period. 23.99% of the stock is currently owned by institutional investors and hedge funds.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.